United States - English - NLM (National Library of Medicine)

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 20 g in 100 ml - mannitol injection is indicated for: - reduction of intracranial pressure and treatment of cerebral edema. - reduction of elevated intraocular pressure. mannitol injection is contraindicated in patients with: - hypersensitivity to mannitol [see warnings and precautions (5.1)] - anuria [see warnings and precautions (5.2)] - severe hypovolemia [see warnings and precautions (5.4)] - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] -   active intracranial bleeding except during craniotomy. the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.  mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .  no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal

United States - English - NLM (National Library of Medicine)

hospira, inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)] . - active intracranial bleeding except during craniotomy. risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data) .no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in resp

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 250 mg in 1 ml - mannitol injection is indicated for the reduction of: - intracranial pressure and treatment of cerebral edema. - elevated intraocular pressure. mannitol injection is contraindicated in patients with: - known hypersensitivity to mannitol [see warnings and precautions (5.1)]. - anuria [see warnings and precautions (5.2)]. - severe hypovolemia [see warnings and precautions (5.4)]. - pre-existing severe pulmonary vascular congestion or pulmonary edema [see warnings and precautions (5.5)]. - active intracranial bleeding except during craniotomy. 8.1 pregnancy risk summary the available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see data).no adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes i

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - mannitol (unii: 3owl53l36a) (mannitol - unii:3owl53l36a) - mannitol 5 g in 100 ml - 5% mannitol is indicated for use as a urologic irrigation fluid for transurethral prostatic resection and other transurethral surgical procedures. 5% mannitol is not for injection. it is contraindicated in patients with anuria.

Kenya - English - Pharmacy and Poisons Board

medisel kenya ltd p.o box 540-01000, thika - mannitol bp - infusion - mannitol bp 20 gm - mannitol

Israel - English - Ministry of Health

eldan electronic instruments co ltd, israel - mannitol - solution for infusion - mannitol 200 mg/ml - mannitol - mannitol 20%, solution for infusion is indicated for: - the promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established; - the reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass; - the reduction of elevated intraocular pressure when the pressure cannot be lowered by other means, and promoting the urinary excretion of toxic substances

Malta - English - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - mannitol - solution for infusion - mannitol 200 mg/l - blood substitutes and perfusion solutions

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 10 per cent - mannitol

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 15 %w/v - mannitol

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - mannitol - solution for infusion - 20 percent weight/volume - solutions producing osmotic diuresis; mannitol